Adam Swank

Initial Public Offerings

Aktis Oncology, a clinical-stage biotechnology company developing radiopharmaceuticals for cancer treatment, on its upsized $365.4 million initial public offering.
J.P. Morgan Securities, Leerink Partners, Piper Sandler & Co. and William Blair & Company as underwriters in the $82 million initial public offering by CAMP4 Therapeutics Corporation.
Curbwaste in various financing transactions, including its $20 million Series B financing.
CINQ Care on its up to $150 million Series C financing.
Adam has represented a number of venture capital funds in connection with their investment activities, including Deerfield Management, Infinity Ventures, Digitalis Ventures, IAG Capital Partners and Guggenheim.
Jefferies, Goldman Sachs & Co. and the other underwriters in connection with the upsized approximately $201 million follow-on offering by Corvus Pharmaceuticals.
J.P. Morgan Securities, Jefferies, Citigroup and TD Securities as underwriters in connection with the approximately $115 million follow-on offering by Vor Biopharma.
Leerink Partners, Cantor Fitzgerald, Stifel, Nicolaus & Company, Oppenheimer & Co. and Baird as underwriters in connection with the approximately $143.8 million public offering and concurrent private placement by Lexeo Therapeutics.
Jefferies, J.P. Morgan Securities and the other underwriters in the $130 million follow-on offering and concurrent registered direct offering by ProKidney Corp.
TD Securities, Cantor Fitzgerald & Co., Stifel, Nicolaus & Company and RBC Capital Markets in the $150 million follow-on offering by COMPASS Pathways plc.
J.P. Morgan Securities as underwriter in the $285 million secondary offering by Harmony Biosciences.
Stifel, Nicolaus & Company, Truist Securities and the other underwriters in connection with the approximately $107 million U.S. initial public offering of TAT Technologies, an Israeli defense and aerospace manufacturer.

At-the-Market Offerings

Jefferies as underwriter in the $90 million follow-on offering by Esperion Therapeutics.
Leerink Partners as underwriter in the approximately $80 million follow-on offering by PepGen Inc.
Leerink Partners and Stifel, Nicolaus & Company as underwriters in Evolus Inc.’s $50 million follow-on offering.
TD Securities and WedBush PacGrow as underwriters in the $100 million follow-on offering by Monte Rosa Therapeutics.
TD Securities, Cantor Fitzgerald & Co., Barclays and other underwriters in multiple follow-on offerings by Humacyte, Inc., aggregating over $90 million.
Jefferies, Cantor Fitzgerald & Co. and the other underwriters in connection with Rezolute, Inc.’s approximately $60 million follow-on offering
Stifel, Nicolaus & Company as underwriter in the $30 million follow-on offering by Precigen, Inc.
Oppenheimer & Co. and Citizens JMP Securities as underwriters in Inovio Pharmaceutical’s approximately $36 million follow-on offering.
D.A. Davidson as underwriter in the approximately $25 million secondary offering by CPI Card Group.
Jefferies as sales agent in multiple at-the-market offering programs, including Achieve Life Sciences, Palladyne AI Corp., Corvus Pharmaceuticals, Vivani Medical, Inc., HOOKIPA Pharma, Valneva SE, Offerpad Solutions Inc., P3 Health Partners and Vuzix Corporation.
TD Securities as sales agent in several at-the-market offering programs, including COMPASS Pathways plc, Repare Therapeutics and Exscientia plc.
Leerink Partners as sales agent in the at-the-market offering programs for Harmony Biosciences and Lexeo Therapeutics.
Piper Sandler & Co. and Cantor Fitzgerald & Co. as sales agents in Arvinas Inc.’s $300 million at-the-market offering program.
Oppenheimer & Co. as sales agent in several at-the-market offering programs, including Inovio Pharmaceuticals, Y-mAbs Therapeutics and Climb Bio.
Stifel, Nicolaus & Company as sales agent in PepGen Inc.’s $100 million at-the-market offering program.
Varonis Systems, a leader in data security, on its offering of $400 million of convertible senior notes and related capped call transactions.
TD Securities and the other underwriters in connection with multiple SEC-registered U.S. public offerings by TD Bank of its senior notes aggregating over $7.7 billion.
TD Securities, BofA Securities, Citigroup, NatWest, Société Générale and the other underwriters in connection with an SEC-registered U.S. public offering by TD Bank of $750 million aggregate principal amount of fixed rate reset limited recourse capital notes due 2085 and fixed rate reset preferred shares.
J.P. Morgan Securities and the other initial purchasers in Blackstone Mortgage Trust’s $450 million offering of senior secured notes.

Capital Markets

Adam SwankAdamSwank

REPRESENTATIONS

NEWS & THOUGHT LEADERSHIP

PRACTICE AREAS